Liposomal daunorubicin is a chemotherapy drug that is FDA approved to treat AIDS related Kaposi’s sarcoma.
Trade name DaunoXome.
Administered intravenously using a liposomal carrier system that provides a favorable pharmokinetic profile at the site of malignant lesions resulting in a 10 fold increase in concentrations compared to conventional dose of daunorubicin.Robison
It is also commonly used to treat specific types of leukaemia and non-Hodgkin lymphoma.